Top

Published in:

01-07-2012 | Research

Molecular Profiling of Parathyroid Hyperplasia, Adenoma and Carcinoma

Authors: Kristóf Árvai, Katalin Nagy, Helga Barti-Juhász, István Peták, Tibor Krenács, Tamás Micsik, Gyula Végső, Ferenc Perner, Béla Szende

Published in: Pathology & Oncology Research | Issue 3/2012

Abstract

The objective of the study was to examine proliferation and apoptosis associated gene expression in the whole sequence parathyroid lesions to reveal specific features of carcinoma. This study was based on surgically removed parathyroid tissues, gene expression analysis was performed both at gene and protein level. First, mRNA isolation was performed from deep-frozen tissue samples, and further apoptosis pathway-specific cDNA macroarray analysis was carried out. The results were validated with real-time PCR. Subsequently, protein expression was analyzed with immunhistochemistry on Tissue Micro Array multi-blocks derived from several paraffin-embedded samples. cDNA macroarrays revealed elevated expression of both pro-apoptotic (FAS receptor, TRAIL ligand, CASPASE8, and −4) and anti-apoptotic (cIAP1, APOLLON) genes in benign proliferative lesions compared to that in normal gland. TMA studies showed overexpression of KI67, P53, SURVIVIN and APOLLON protein and failure of expression of P27, BCL2, BAX, CHROMOGRANIN-A, SYNAPTOPHYSIN, CYCLIND1, FLIP, TRAIL, CK8, CK18, CK19 in parathyroid carcinoma was detected. These alterations in gene expression of the investigated products could be used in differentiation between beningn and malignant proliferative processes of the parathyroid gland. Authors conclude that a series of alterations in gene expression such as overexpression of APOLLON, P53, KI67 and suppression of P27, BCL2, BAX lead to uncontrolled cell proliferation, but still not leading to increased apoptotic activity in parathyroid carcinoma.

Fernandez-Ranvier GG, Khanafshar E, Jensen K et al (2007) Parathyroid carcinoma, atypical parathyroid adenoma, or parathyromatosis? Cancer 110(2):255–264PubMedCrossRef

Adami S, Marcocci C, Gatti D. Epidemiology of primary hyperparathyroidism in Europe. J Bone Miner Res 17 Suppl 2:N18-23

Marx SJ (2000) Hyperparathyroid and hypoparathyroid disorders. N Engl J Med 343:1863–1875PubMedCrossRef

Fernandez-Ranvier GG, Khanafshar E, Tacha D et al (2009) Defining a molecular phenotype for benign and malignant parathyroid tumors. Cancer 115(2):334–344PubMedCrossRef

Stojadinovic A, Hoos A, Nissan A et al (2003) Parathyroid neoplasms: clinical, histopathological, and tissue microarray-based molecular analysis. Hum Pathol 34(1):54–64PubMedCrossRef

Szende B, Farid P, Végso G et al (2004) Apoptosis and P53, Bcl-2 and Bax gene expression in parathyroid glands of patients with hyperparathyroidism. Pathol Oncol Res 10(2):98–103PubMedCrossRef

Vargas MP, Vargas HI, Kleiner DE et al (1997) The role of prognostic markers (MiB-1, RB, and bcl-2) in the diagnosis of parathyroid tumors. Mod Pathol 10(1):12–17PubMed

Hadar T, Shvero J, Yaniv E et al (2005) Expression of p53, Ki-67 and Bcl-2 in parathyroid adenoma and residual normal tissue. Pathol Oncol Res 11(1):45–49PubMedCrossRef

Szende B, Arvai K, Peták I et al (2006) Changes in gene expression in the course of proliferative processes in the parathyroid gland. Magy Onkol 50(2):137–140PubMed

10.

Solcia E, Kloppel G, Sobin LH (2000) Histological typing of endocrine tumours; international histological classification of tumours. WHO Ed. 2. Springer; p.48–55

11.

Shane E, Bilezikian JP (1982) Parathyroid carcinoma: a review of 62 patients. Endocr Rev 3(2):218–226PubMedCrossRef

12.

Favia G, Lumachi F, Polistina F et al (1998) Parathyroid carcinoma: sixteen new cases and suggestions for correct management. World J Surg 22(12):1225–1230PubMedCrossRef

13.

Hundahl SA, Fleming ID, Fremgen AM et al (1999) Two hundred eighty-six cases of parathyroid carcinoma treated in the U.S. between 1985–1995: a National Cancer Data Base Report. Cancer 1;86(3):538–44

14.

Busaidy NL, Jimenez C, Habra MA et al (2004) Parathyroid carcinoma: a 22-year experience. Head Neck 26(8):716–726PubMedCrossRef

15.

Haven CJ, Howell VM, Eilers PH et al (2004) Gene expression of parathyroid tumors: molecular subclassification and identification of the potential malignant phenotype. Cancer Res 64(20):7405–7411PubMedCrossRef

16.

Woodard GE, Lin L, Zhang JH et al (2005) Parafibromin, product of the hyperparathyroidism-jaw tumor syndrome gene HRPT2, regulates cyclin D1/PRAD1 expression. Oncogene 10;24(7):1272–6

17.

Cetani F, Pardi E, Ambrogini E et al (2007) Different somatic alterations of the HRPT2 gene in a patient with recurrent sporadic primary hyperparathyroidism carrying an HRPT2 germline mutation. Endocr Relat Cancer 14(2):493–499PubMedCrossRef

18.

Iacobone M, Masi G, Barzon L et al (2009) Hyperparathyroidism-jaw tumor syndrome: a report of three large kindred. Langenbecks Arch Surg 394(5):817–825PubMedCrossRef

19.

Yang Y-J, Han J-W, Youn H-D et al (2010) The tumor suppressor, parafibromin, mediates histone H3 K9 methylation for cyclin D1 repression. Nucleic Acids Res 38:382–390PubMedCrossRef

20.

Masi G, Barzon L, Iacobone M et al (2008) Clinical, genetic, and histopathologic investigation of CDC73-related familial hyperparathyroidism. Endocr Relat Cancer 15(4):1115–1126PubMedCrossRef

21.

Shih RY, Fackler S, Maturo S et al (2009) Parathyroid carcinoma in multiple endocrine neoplasia type 1 with a classic germline mutation. Endocr Pract 15(6):567–572PubMedCrossRef

22.

Cetani F, Ambrogini E, Viacava P et al (2007) Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma? Eur J Endocrinol 156(5):547–554PubMedCrossRef

23.

Howell VM, Gill A, Clarkson A et al (2009) Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma. J Clin Endocrinol Metab 94(2):434–441PubMedCrossRef

Title: Molecular Profiling of Parathyroid Hyperplasia, Adenoma and Carcinoma
Authors: Kristóf Árvai
Katalin Nagy
Helga Barti-Juhász
István Peták
Tibor Krenács
Tamás Micsik
Gyula Végső
Ferenc Perner
Béla Szende
Publication date: 01-07-2012
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 3/2012
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-011-9483-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2012

Expression of GLUT1 and GLUT3 Glucose Transporters in Endometrial and Breast Cancers

Association of GSTM1, GSTT1, GSTP1 and CYP2E1 Single Nucleotide Polymorphisms with Colorectal Cancer in Iran

Epithelial-To-Mesenchymal Transition Induced by Freund’s Adjuvant Treatment in Rat Mesothelial Cells: A Morphological and Immunocytochemical Study

Improving the Reproducibility of the Gleason Scores in Small Foci of Prostate Cancer - Suggestion of Diagnostic Criteria for Glandular Fusion

Immunodetection of SV40 T/t-antigens in Human Osteosrcoma in a Series of Tunisian Patients

Angiogenesis and Survival in Patients with Myelodysplastic Syndrome

Keynote webinar | Spotlight on antibody–drug conjugates in cancer